TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23299530
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg
Study: 6179337
Drug: UVB exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB exposure 2-3 times weekly for 4 weeks
Study: 6179337
Drug: UVA exposure
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA exposure 2-3 times weekly for 4 weeks
Study: 6179337
Drug: PUVA exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA exposure 2-3 times weekly for 4 weeks
Study: 16123958
Drug: Delayed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6) with daclizumab and mycophenolate mofetil
Study: 12069736
Drug: Buserelin 150
Normalized name: buserelin 150 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin 150 microg nasal spray three times daily (Group B)
Study: 12069736
Drug: Nafarelin nasal
Normalized name: nafarelin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin nasal spray 400 microg twice daily (Group N)
Study: 12069736
Drug: Leuprorelin depot
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L)
Study: 3304348
Drug: Cefazolin sodium,
Normalized name: CeFAZolin Sodium, 1 g/10 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin sodium, 1 g intravenously, one hour prior to surgery and a similar dose eight hours later
Study: 24670351
Drug: Krka's formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krka's formulation of clopidogrel under fasting conditions
Study: 24670351
Drug: Innovator's formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator's formulation of clopidogrel under fed conditions
Study: 24670351
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of clopidogrel
Study: 11951812
Drug: Controlled-release alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release alpha-lipoic acid (CRLA) 900 mg daily for 6 weeks, then 1200 mg daily for an additional 6 weeks
Study: 11951812
Drug: Controlled-release alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release alpha-lipoic acid (CRLA)
Study: 10402336
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 1 mg/kg
Study: 8918852
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention addressing AAS effects, sports nutrition, strength-training alternatives, drug refusal role play, anti-AAS media messages, and weight-room sessions.
Study: 9609217
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose heparin or warfarin
Study: 503385
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) gel (0.5 mg PGE2) intracervically
Study: 27180890
Drug: Macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan 10 mg once daily
Study: 31900959
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily
Study: 17513655
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (lidocaine and remifentanil)
Study: 22508772
Drug: apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 20 mg twice daily
Study: 23485720
Drug: Lactulose therapy
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose therapy
Study: 11422660
Drug: Control (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (NaCl infusion)
Study: 3027884
Drug: Tinidazole treatment
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole treatment for 5 days
Study: 22615318
Drug: Tinidazole treatment
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole treatment
Study: 31535332
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14)
Study: 29889698
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (1 mg)
Study: 8780333
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg)
Study: 2677125
Drug: lofepramine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: lofepramine (70 mg, 105 mg, 140 mg)
Study: 699626
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg aspirin 4-times daily
Study: 699626
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aspirin 4-times daily
Study: 30705241
Drug: Dysarthria therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysarthria therapy via Skype
Study: 25176266
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser irradiation of blood (ILIB) with semiconductor laser (wavelength - 0.67 microns, power output - 3-2 mW) in addition to standard treatment
Study: 25176266
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser irradiation of blood (ILIB) with semiconductor laser
Study: 15059282
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg/day for one week, with weaning over a second week)
Study: 11384567
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of pilocarpine and latanoprost
Study: 11384567
Drug: Latanoprost (0.005%)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) once daily to one eye and vehicle to the other
Study: 30085184
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (DT) with a ritonavir‐boosted PI (PI/r) plus lamivudine
Study: 30085184
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) with PI/r plus two nucleos(t)ide reverse transcriptase inhibitors (N(t)RTIs)
Study: 24865619
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management treatment
Study: 16621194
Drug: Pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent vaccine (G1, G2, G3, G4, and P1A)
Study: 16621194
Drug: Monovalent P1A
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent P1A vaccine
Study: 11236243
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of G-CSF and CEA
Study: 29505522
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (VT ≥ 8 mL/kg) + pressure controlled ventilation (PCV)
Study: 26811112
Drug: Preoperative hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hemoglobin <13 g/dL
Study: 21069899
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an effect-site concentration of 2.0 ng/ml (RF₂(.)₀)
Study: 21069899
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an effect-site concentration of 2.5 ng/ml (RF₂(.)₅)
Study: 6426073
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 10 mg inhaled from a pressurised metered dose inhaler
Study: 30990550
Drug: Doxepin mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin mouthwash (25 mg/5 mL water)
Study: 17303494
Drug: Misoprostol 6-8
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 6-8 hours after mifepristone treatment
Study: 17303494
Drug: Misoprostol 24
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 24 hours after mifepristone treatment
Study: 19238647
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine spray plus 2% lidocaine jelly lubrication
Study: 9011481
Drug: High-dose interferon-alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alpha2b (10 MU administered subcutaneously daily until normalization of serum transaminase concentrations)
Study: 9011481
Drug: High-dose interferon-alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alpha2b
Study: 31434028
Drug: Nicotine-containing e-cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-containing e-cigarettes (6 mg/mL)
Study: 24584988
Drug: Standard ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ACT (N=85) - provided standard assertive community treatment
Study: 22910929
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (CR and TT)
Study: 20417565
Drug: Myoconjunctival PMMA
Normalized name: pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myoconjunctival PMMA implant
Study: 20417565
Drug: Traditional PMMA
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional PMMA implant
Study: 20417565
Drug: Porous polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous polyethylene implant
Study: 18826868
Drug: Trileptal oral
Normalized name: Trileptal Oral Product
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trileptal oral suspension (300 mg)
Study: 18826868
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (300 mg)
Study: 15915007
Drug: formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol DPI (Aerolizer, 12-microg dose)
Study: 10382128
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate and a 2-week course of bismuth subcitrate, amoxicillin, and metronidazole (Group A)
Study: 10382128
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate and a 2-week course of placebo (Group C)
Study: 9715289
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow oxygen (O2) inhalation
Study: 2057244
Drug: EXOSURF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXOSURF (5 mL/kg intratracheally)
Study: 2057244
Drug: Control (air
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (air 5 mL/kg intratracheally)
Study: 30849345
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept monotherapy (IAI)
Study: 30849345
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept plus rescue photodynamic therapy (IAI + rPDT)
Study: 26011140
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care management (daily oral hydration and diclofenac 75 mg IM on demand)
Study: 26011140
Drug: Alfuzosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin therapy
Study: 2764269
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch solution (HD-HES group, n = 15, ratio of replacement 1:1)
Study: 29268598
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg)
Study: 16489524
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment (placebo)
Study: 25542604
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment
Study: 12800795
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery followed by immunotherapy
Study: 8468720
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 plus lymphokine-activated killer (LAK) cells
Study: 8468720
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 alone
Study: 8468720
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 plus LAK cells
Study: 8468720
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 plus LAK cells (melanoma subgroup)
Study: 8468720
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 alone (melanoma subgroup)
Study: 25416075
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS)
Study: 15688235
Drug: Polidocanol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol (5 mg/ml)
Study: 7784025
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 7.5 mg
Study: 2327885
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hospital-supervised bicycling with home walking
Study: 30273493
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (2 × 200 mg/day for 8 weeks)
Study: 22147903
Drug: Simvastatin/Ezetimibe combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/Ezetimibe combination
Study: 18050627
Drug: Acupuncture group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture group (n=30) with manual acupuncture stimulation of Ganshu (BL18), Pishu (BL20), Zusanli (ST 36), once daily for 30 days, in addition to diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Study: 18050627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=24) with diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Study: 10615719
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (2‐mg or 8‐mg tablets; maximum daily dose 8 mg)
Study: 10615719
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (racemic D ‐/+ L‐methadone; maximum daily dose 80 mg)
Study: 8960988
Drug: Intravaginal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal and oral misoprostol (100 micrograms intravaginally followed by 100 micrograms p.o. every 2 h)
Study: 8960988
Drug: Oxytocin/PGE2 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin/PGE2 gel (PGE2 cervical instillation 6 h before continuous oxytocin infusion)
Study: 8960988
Drug: Oxytocin/PGE2 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin/PGE2 gel
Study: 11823757
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Study: 2073711
Drug: Metrifonate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 2.5 mg/kg
Study: 2073711
Drug: Metrifonate 5
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 5 mg/kg
Study: 2073711
Drug: Metrifonate 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 7.5 mg/kg
Study: 2073711
Drug: Metrifonate 15
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 15 mg/kg
Study: 9210002
Drug: Acyclovir treatment
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir treatment
Study: 25567476
Drug: Subcutaneous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous methylnaltrexone bromide 12 mg (MNTX group)
Study: 23135087
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% spray (monotherapy or add-on therapy)
Study: 15983792
Drug: Methylphenidate 40
Normalized name: METHYLPHENIDATE 40MG 24HR SA CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 40 mg
Study: 16884978
Drug: Morphine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (40 mg)
Study: 17061994
Drug: Corticosteroid withdrawal
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid withdrawal (1 mg/month)
Study: 15261314
Drug: Dual-injection technique
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-injection technique (Group 2)
Study: 15261314
Drug: Single-injection technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection technique (Group 1)
Study: 11192132
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg + metformin
Study: 11192132
Drug: Open-label pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label pioglitazone + metformin
Study: 9359980
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg/day)
Study: 9291759
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol
Study: 3937407
Drug: Misoprostol (Mi)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (Mi) 100 mcg, 4 doses/day
Study: 28774880
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle
Study: 21444799
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg) administered orally 1 h before each treatment session
Study: 21444799
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally 1 h before each treatment session
Study: 9576141
Drug: FP 100
Normalized name: Peanut Allergen-dnfp 100 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 100 microg, twice daily for 8 weeks
Study: 3103169
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oral aspirin
Study: 23680817
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg/day) plus modular CBT for 16 weeks, followed by maintenance escitalopram for 28 weeks
Study: 23680817
Drug: Escitalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram plus CBT followed by pill placebo
Study: 8380567
Drug: 72 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 Gy hyperfractionated radiation therapy + BCNU (80 mg/m2 on days 3, 4, 5 of radiation therapy and then every 8 weeks for 1 year)
Study: 8380567
Drug: 81.6 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81.6 Gy hyperfractionated radiation therapy + BCNU
Study: 3717993
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to respond to treatment
Study: 26350485
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injections (control)
Study: 20575258
Drug: DTaP-Hib vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-Hib vaccine
Study: 12093769
Drug: Doppler strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler strain rate echocardiography during dobutamine infusion
Study: 6182343
Drug: Aggressive protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive protocol using adriamycin, cyclophosphamide, vincristine, dacarbazine for remission induction; additional randomized group received high dose β‐interferon.
Study: 29703286
Drug: Riboflavin administration
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin administration every 1 minute during UV-A exposure at 3mW/cm2
Study: 7131548
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg)
Study: 12891248
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg/day)
Study: 14580034
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injections, dosage 10 to 50 U per site, total dose up to 200 U in the masticatory system, maximum 400 U if other sites included, injection frequency no more than once every 12 weeks.
Study: 14580034
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections for chronic myofascial trigger points in painful muscles without observable involuntary movements.